Phase 3 clinical trial results of RG1068 to be discussed

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Dec 9 2009Repligen Corporation

Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Wednesday, December 9th, 2009 at 8:30 a.m. EST, to discuss results of its Phase 3 clinical trial of RG1068 in MRI imaging of the pancreas.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 804-6924 for domestic calls and (857) 350-1670 for international calls. Participants must provide the following passcode: 87770260. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at www.repligen.com.

Source:

Repligen Corporation

Posted in: Disease/Infection News

Tags: , , , , ,

Comments (0)

Suggested Reading

Can psychedelics improve sexual functioning and satisfaction?
Reduction of prenatal depression associated with higher full-term birth rates
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat
Korean fermented food Doenjang shows promise in alleviating menopausal symptoms
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth
Mediterranean diet and exercise reshape gut microbiome, aiding weight loss

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New model predicts kidney injury risk in cancer patients on cisplatin